Pediatrics

August 11, 2022

"An unmet need is a biomarker that distinguishes active lupus nephritis, particularly important in pediatrics where minimizing invasive procedures is desirable.”

March 04, 2022

The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.

February 23, 2022

Susan Shenoi, MBBS, MS, discusses the recent developments in pediatric rheumatology as well as new therapies and guidelines for treating juvenile idiopathic arthritis.

February 02, 2022

As telehealth is an emerging and rapidly changing form of pediatric rheumatology care, engaging patients, caregivers, and rheumatologists will help streamline care to improve satisfaction and overall experience.

August 05, 2021

Although it is assumed that fatigue is related to inflammation, disease activity, or treatment with drugs such as Methotrexate, it can affect children independent of disease activity and impacted by psychosocial factors.

June 23, 2021

The American College of Rheumatology has updated its treatment guidelines for the management of pediatric rheumatic disease during the COVID-19 pandemic. The guideline includes 33 final guidance recommendations, 8 of which received moderate-to-high task force consensus.

October 05, 2020

In juvenile idiopathic arthritis, predictive genomic risk scores may enhance current diagnosis protocols, prioritizing higher-risk patients for follow-up and reducing treatment delays, according to a study published this month in Annals of Rheumatic Diseases.

September 30, 2020

Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.

January 31, 2020

A 20-month-old boy with skin peeling, a strawberry red tongue and swelling of the hands and feet. Can you diagnose this patient?

December 20, 2019

The U.S. Food and Drug Administration has approved rituximab (Rituxan, Genentech) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids, to fulfil an unmet medical need for these rare and serious diseases in children.